Mapping the Diagnostic Odyssey of Congenital Disorders of Glycosylation (CDG): Insights from the Community

Overview

Journal Orphanet J Rare Dis

Publisher Biomed Central

Specialty General Medicine

Date 2024 Nov 1

PMID 39482754

Authors

Pedro Granjo

Carlota Pascoal

Diana Gallego

Rita Francisco

Jaak Jaeken

Tristen Moors

Andrew C Edmondson

Kristin A Kantautas

Mercedes Serrano

Paula A Videira

Vanessa Dos Reis Ferreira

Affiliations

Soon will be listed here.

Abstract

Background: Congenital disorders of glycosylation (CDG) are a group of rare metabolic diseases with heterogeneous presentations, leading to substantial diagnostic challenges, which are poorly understood. Therefore, this study aims to elucidate this diagnostic journey by examining families' and professionals' experiences.

Results And Discussion: A questionnaire was designed for CDG families and professionals, garnering 160 and 35 responses, respectively. Analysis revealed the lack of seizures as a distinctive feature between PMM2-CDG (11.2%) with Other CDG (57.7%) at symptom onset. Hypotonia and developmental disability were prevalent symptoms across all studied CDG. Feeding problems were identified as an early onset symptom in PMM2-CDG (Cramer's V (V) = 0.30, False Discovery Rate (FDR) = 3.8 × 10), and hypotonia in all studied CDG (V = 0.34, FDR = 7.0 × 10). The average time to diagnosis has decreased in recent years (now ~ 3.9 years), due to advancements namely the increased use of whole genome and exome sequencing. However, misdiagnoses remain prevalent (PMM2-CDG - 44.9%, non-PMM2-CDG - 64.8%). To address these challenges, we propose adapting medical training to increase awareness of CDG and other rare diseases, ongoing education for physicians, the development of educational resources for relevant medical units, and empowerment of families through patient organizations and support networks.

Conclusion: This study emphasizes the crucial role of community-centered research, and the insights families can offer to enhance CDG management. By pinpointing existing gaps and needs, our findings can inform targeted interventions and support systems to improve the lives of those impacted by CDG.

References

Ramalle-Gomara E, Ruiz E, Quinones C, Andres S, Iruzubieta J, Gil-de-Gomez J . General knowledge and opinion of future health care and non-health care professionals on rare diseases. J Eval Clin Pract. 2014; 21(2):198-201. DOI: 10.1111/jep.12281. View

Chang I, He M, Lam C . Congenital disorders of glycosylation. Ann Transl Med. 2019; 6(24):477. PMC: 6331365. DOI: 10.21037/atm.2018.10.45. View

Pascoal C, Ferreira I, Teixeira C, Almeida E, Slade A, Brasil S . Patient reported outcomes for phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG): listening to what matters for the patients and health professionals. Orphanet J Rare Dis. 2022; 17(1):398. PMC: 9618201. DOI: 10.1186/s13023-022-02551-y. View

Francisco R, Brasil S, Pascoal C, Edmondson A, Jaeken J, Videira P . A Community-Led Approach as a Guide to Overcome Challenges for Therapy Research in Congenital Disorders of Glycosylation. Int J Environ Res Public Health. 2022; 19(11). PMC: 9180837. DOI: 10.3390/ijerph19116829. View

Lumsden J, Urv T . The Rare Diseases Clinical Research Network: a model for clinical trial readiness. Ther Adv Rare Dis. 2023; 4:26330040231219272. PMC: 10752072. DOI: 10.1177/26330040231219272. View

Sreih A, Cronin K, Shaw D, Young K, Burroughs C, Kullman J . Diagnostic delays in vasculitis and factors associated with time to diagnosis. Orphanet J Rare Dis. 2021; 16(1):184. PMC: 8059170. DOI: 10.1186/s13023-021-01794-5. View

Starosta R, Tarnowski J, Pinto E Vairo F, Raymond K, Preston G, Morava E . Bosch-Boonstra-Schaaf optic atrophy syndrome (BBSOAS) initially diagnosed as ALG6-CDG: Functional evidence for benignity of the ALG6 c.391T>C (p.Tyr131His) variant and further expanding the BBSOAS phenotype. Eur J Med Genet. 2020; 63(7):103941. DOI: 10.1016/j.ejmg.2020.103941. View

Taruscio D, Baynam G, Cederroth H, Groft S, Klee E, Kosaki K . The Undiagnosed Diseases Network International: Five years and more!. Mol Genet Metab. 2020; 129(4):243-254. DOI: 10.1016/j.ymgme.2020.01.004. View

Wainstock D, Katz A . Advancing rare disease policy in Latin America: a call to action. Lancet Reg Health Am. 2023; 18:100434. PMC: 9950655. DOI: 10.1016/j.lana.2023.100434. View

10.

Bogdanska A, Lipinski P, Szymanska-Rozek P, Jezela-Stanek A, Rokicki D, Socha P . Clinical, biochemical and molecular phenotype of congenital disorders of glycosylation: long-term follow-up. Orphanet J Rare Dis. 2021; 16(1):17. PMC: 7789416. DOI: 10.1186/s13023-020-01657-5. View

11.

Nguyen C, Kariyawasam D, Alba-Concepcion K, Grattan S, Hetherington K, Wakefield C . 'Advocacy groups are the connectors': Experiences and contributions of rare disease patient organization leaders in advanced neurotherapeutics. Health Expect. 2022; 25(6):3175-3191. PMC: 9700154. DOI: 10.1111/hex.13625. View

12.

Lefeber D, Morava E, Jaeken J . How to find and diagnose a CDG due to defective N-glycosylation. J Inherit Metab Dis. 2011; 34(4):849-52. PMC: 3137781. DOI: 10.1007/s10545-011-9370-0. View

13.

Tumiene B, Graessner H, Mathijssen I, Pereira A, Schaefer F, Scarpa M . European Reference Networks: challenges and opportunities. J Community Genet. 2021; 12(2):217-229. PMC: 7968406. DOI: 10.1007/s12687-021-00521-8. View

14.

Clark D, Murray T, Drees M, Kulkarni N . A Case of ALG6-CDG with Explosive Onset of Intractable Epilepsy During Infancy. Child Neurol Open. 2023; 10:2329048X231153781. PMC: 9900650. DOI: 10.1177/2329048X231153781. View

15.

Iyer S, Sam F, DiPrimio N, Preston G, Verheijen J, Murthy K . Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG. Dis Model Mech. 2019; 12(11). PMC: 6899038. DOI: 10.1242/dmm.040584. View

16.

Magerl M, Gothe H, Krupka S, Lachmann A, Ohlmeier C . A Germany-wide survey study on the patient journey of patients with hereditary angioedema. Orphanet J Rare Dis. 2020; 15(1):221. PMC: 7448463. DOI: 10.1186/s13023-020-01506-5. View

17.

Witters P, Tahata S, Barone R, Ounap K, Salvarinova R, Gronborg S . Clinical and biochemical improvement with galactose supplementation in SLC35A2-CDG. Genet Med. 2020; 22(6):1102-1107. PMC: 7275909. DOI: 10.1038/s41436-020-0767-8. View

18.

Bruneel A, Cholet S, Tran N, Mai T, Fenaille F . CDG biochemical screening: Where do we stand?. Biochim Biophys Acta Gen Subj. 2020; 1864(10):129652. DOI: 10.1016/j.bbagen.2020.129652. View

19.

Bayat A, Knaus A, Pendziwiat M, Afenjar A, Barakat T, Bosch F . Lessons learned from 40 novel PIGA patients and a review of the literature. Epilepsia. 2020; 61(6):1142-1155. DOI: 10.1111/epi.16545. View

20.

Brasil S, Pascoal C, Francisco R, Dos Reis Ferreira V, Videira P, Valadao A . Artificial Intelligence (AI) in Rare Diseases: Is the Future Brighter?. Genes (Basel). 2019; 10(12). PMC: 6947640. DOI: 10.3390/genes10120978. View